Search the Newsreel

Estrella Immunopharma Inc (ESLA) Stock News Today

This article provides current stock information for Estrella Immunopharma Inc (ESLA), noting its recent price of $0.723 USD, a drop of 4.01%. It mentions that news and analysis, financials, stock score, technical forecast, ownership, dividends, and profile information are available, with more news expected …

Simmons First National Corporation $SFNC Holdings Raised by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Simmons First National Corporation (SFNC) by 213.2% in the first quarter, now holding 206,793 shares valued at approximately $4.02 million. This move is part of broader institutional investor activity, with hedge funds and other investors …

Noticias de acciones de BitMine Immersion Technologies Ord Shs (BMNR)

Immersion (NASDAQ:IMMR) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?

Immersion (NASDAQ:IMMR) shares have moved above their 200-day moving average, trading at $7.60 with a 200-day average of $6.42. The company recently beat quarterly earnings expectations, reporting $0.12 EPS against a $0.05 forecast and $270 million in revenue, also declaring a quarterly dividend of …

Shimmick (NASDAQ:SHIM) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded Shimmick (NASDAQ:SHIM) from a "hold" to a "sell" rating, while Weiss Ratings reaffirmed its "sell" rating. Despite these downgrades, MarketBeat's consensus rating for Shimmick remains "Hold" with an average price target of $5.50. Shimmick's stock opened at $4.42, with a …

ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value

ImmunityBio (IBRX) has shown strong stock performance with a 321.9% gain over three years, driven by recent approvals for ANKTIVA. However, the stock appears overvalued based on its current Price-to-Sales (P/S) ratio of 46.8x, significantly higher than the biotech industry average. While there is …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7% - Here's What Happened

Immix Biopharma (NASDAQ: IMMX) saw its stock price drop by 6.7% to $9.39 during midday trading on Friday, with trading volume significantly lower than average. Despite this decline, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of …

Immutep Ltd (IMMP) Stock News Today

This article provides a brief update on Immutep Ltd (IMMP) stock news. It states that more news will be coming soon regarding the company's earnings, analyst ratings, and key developments. The page also displays current stock information for IMMP, including its price, daily change, …

Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings, reporting an EPS of ($0.18), which slightly missed the consensus estimate of ($0.17). Following the news, shares dropped 3.4% to $9.72, significantly below the average analyst target price of $20.71. Despite the earnings miss, the company holds …

Scinai Immunotherapeutics Ltd (SCNI) Stock News Today

This article provides an overview of Scinai Immunotherapeutics Ltd (SCNI) stock information from TradingKey. It shows the current stock price, recent performance, market capitalization, and various financial and analytical tools available on the platform. The news section indicates that more updates are expected soon.

Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Scinai Immunotherapeutics Ltd (SCNI), noting that no specific earnings forecast score is available for the company, contrasting with the Biotechnology & Medical Research industry average. It highlights the current stock price, market capitalization, and indicates that relevant …

Shimmick Corp expected to post a loss of 2 cents a share - Earnings Preview

Shimmick Corp is expected to report a loss of 2 cents per share, according to an earnings preview. This information was sourced from Refinitiv and highlighted by TradingView News.

Altimmune, Inc. (ALT) options chain – Yahoo Finance

This article displays the options chain for Altimmune, Inc. (ALT) as of August 7, 2026. It includes detailed call and put option data such as strike prices, last prices, changes, volume, and open interest for August 21, 2026, expiry. The current stock price and …

Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash

Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 million

Immix Biopharma reported a widened net loss of USD 11.56 million for Q2 FY26, compared to USD 6.62 million in the previous year. This increase was primarily driven by general and administrative expenses more than doubling to USD 7.12 million due to higher compensation …

Earnings To Watch: Shimmick Corp (SHIM) Q2 2026 -- GF Value Sees 42% Downside

Shimmick Corp (SHIM) is slated to release its Q2 2026 earnings on August 10, 2026, with analysts forecasting $121.85 million in revenue and an EPS of -0.06. While analysts project a 55.50% upside from the current price based on average price targets, GuruFocus estimates …

Immutep Ltd (IMMP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Immunocore (IMCR) reported a Q2 2026 loss of 2 cents per share, wider than analyst estimates, despite revenues of $115.9 million, which beat expectations and increased 18.3% year-over-year. The revenue growth was primarily driven by strong sales of its drug Kimmtrak in the U.S. …

Immunome CBO Kinney Horn sells $2.27m in company stock

Immunome's Chief Business Officer, Kinney Horn, sold 90,616 shares of company stock for $2.27 million after exercising employee stock options. This transaction occurred when the stock was near its 52-week high and followed a 162% gain over the past year. InvestingPro analysis suggests the …

Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT

Renaissance Technologies LLC has acquired a new stake of $4.78 million in Immunovant, Inc. (NASDAQ:IMVT), while institutional investors collectively own 47.08% of the company's stock. Despite analysts maintaining a "Moderate Buy" rating with an average target price of $44, Immunovant insiders have sold approximately …

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 4.3% over the past four weeks to close the last trading session at $34.5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts …

Wilsey Asset Management Inc. Has $36.32 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Wilsey Asset Management Inc. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the second quarter, bringing its total holdings to 421,867 shares valued at $36.32 million. The medical equipment provider recently reported strong Q2 earnings, beating analyst estimates with $2.18 …

Immunocore Holdings plc 2026: Revenue $115.93M, EPS ($0.02) — 10-Q Summary

Immunocore Holdings plc (IMCR) reported strong financial results for the quarter ended 2026, with revenue increasing to $115.93M from $97.96M year-over-year. The company significantly reduced its net loss to $808K (EPS ($0.02)) compared to a $10.3M loss (EPS ($0.2)) in the prior-year quarter. This …

Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Estrella Immunopharma Inc (ESLA), detailing its current stock performance, market capitalization, and analyst ratings. It indicates a "Strong Buy" rating with a significant upside potential based on an updated analyst target price. The article also includes historical …

Évaluations, estimations et prévisions d’analystes pour OSE Immunotherapeutics SA (6OP.HM)

Immersion Corp (IMMR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immersion Corp (IMMR), detailing its current price momentum score, support and resistance levels, and the readings from various technical indicators and moving averages. It suggests that the stock is suitable for range-bound swing trading given its current …

Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates

AC Immune earnings missed by CHF0.18, revenue fell short of estimates

How Strong H1 Profits and Kimtrak Survival Data At Immunocore (IMCR) Have Changed Its Investment Story

Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-period loss to net income of US$12.16 million. Alongside these figures, management …

ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise …

Persimmon: What We Think of the Stock After Earnings

Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quarter 2026 revenue of US$51.24 million and a net loss of US$230.38 million. The …

Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance

Lyell Immunopharma reported a GAAP net loss of $44.8 million for Q2 2026 and held $228.0 million in cash, expecting this to last into Q3 2027. The company announced advancing clinical milestones for its ronde-cel and LYL273 programs, including ongoing trials and upcoming data …

Zimmer Biomet Holdings (ZBH) Following Its Beat And Guidance Lift, Is The Valuation Catching Up?

Zimmer Biomet Holdings (ZBH) recently reported stronger-than-expected quarterly results and increased its guidance, driven by solid execution in U.S. hip and technology lines and sales force restructuring progress. Despite a significant 5-year decline in shareholder return, the company's recent 90-day share price return of …

Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07